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In this study, 132 patients with lymphadenopathy were investigated. Fifty-two (39.4%) were diagnosed with tuberculosis (TB).
The microscopic observation drug susceptibility (MODS) assay provided rapid (13 days), accurate diagnosis (sensitivity, 65.4%)
and reliable drug susceptibility testing (DST). Despite its lower sensitivity than that of other methods, its faster results and si-
multaneous DST are advantageous in resource-poor settings, supporting the incorporation of MODS into diagnostic algorithms
for extrapulmonary TB.
In 2013, 14.5% of new tuberculosis (TB) notifications worldwidewere extrapulmonary (1), and in certain regions this percentage
was much higher (2). Nonspecific disease manifestations and
paucibacillary infection make diagnosing extrapulmonary TB
challenging (3, 4). Culture, the diagnostic gold standard, allows
identification to the species level and drug susceptibility testing
(DST) (5), but generating results takes several weeks; automated
liquid culture systems are relatively faster (6), but financial con-
straints limit their use.
The microscopic observation drug susceptibility (MODS) as-
say is a low-cost, liquid culture-based diagnostic assay for TB (7,
8). With accuracy comparable to that of other culture techniques
(7, 9, 10), MODS is faster (7), provides simultaneous DST (10–
13), and has World Health Organization (WHO) approval for
direct testing of sputum specimens in low-resource settings (14,
15).MODS accurately diagnoses TB from cerebrospinal fluid (16)
and pleural specimens (17), but its role in the diagnosis of solid
tissue TB remains unknown. This prospective cross-sectional
study was designed to investigate the use of MODS for culture of
lymph node tissue in an operational setting.
Patients18 years old with lymphadenopathy requiring diag-
nostic tissue sampling were recruited consecutively from three
public hospitals in Lima, Peru, over 14 months. Ethical ap-
proval was obtained from the Institutional Ethics Committee of
the Universidad Peruana Cayetano Heredia, Asociación Benéfica
PRISMA, and each hospital’s ethics approval committee. All pa-
tients provided written informed consent. For each patient, clin-
ical and demographic data were collected and the treating physi-
cian was asked to give the most likely diagnosis. Patients with
unknown HIV status were offered testing.
Tissue sampling was performed routinely, and samples were
immediately divided into three equal parts and processed as out-
lined in Fig. 1. MODS was performed in accordance with pub-
lished standard operating procedures (18). The microbiological
criterion for TB was positivity by at least one of the following:
auraminemicroscopy,MODS, or Löwenstein-Jensen (LJ) culture.
Strains obtained by LJ culture underwent phenotypic DST by the
proportion method, which was performed at the national TB ref-
erence laboratory, and the in-house tetrazolium microplate assay
(TEMA). Samples for histological evaluation were sealed in par-
affin blocks and reported routinely. Once recruitment was ended,
the blocks were retrieved and slides were fixed and stained with
hematoxylin-eosin, Ziehl-Neelsen (ZN), and periodic acid-Schiff
stains. Three independent pathologists blind to the clinical data
recorded the presence of acid-fast bacilli (AFB), granulomas, and
caseating necrosis and gave an overall diagnosis. A histological
definition of TB required concordance between two or more pa-
thologists; when retrieval of paraffin blocks was not possible (n
11), the hospital pathology report was obtained, and if TB was
identified, this was used. TB was diagnosed when microbiological
and/or histological criteria were met.
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Data were entered into Excel and analyzed by Stata version 12
(StataCorp). Nominal demographic data and test characteristics
were compared by Fisher’s exact test. Times to results were com-
pared by the Mann-Whitney U test. A P value of0.05 was con-
sidered significant. Agreement between pathologists was assessed
by using Cohen’s kappa coefficient for multiple ratings; a kappa
value of0.81 was taken to indicate substantial agreement (19).
One hundred forty-four specimens from 132 patients were
tested. Patient demographics are presented in Table 1. Fifty-two
patients (39.4%) were diagnosed with TB (Table 1; Fig. 2, top).
Nineteen were positive by auramine microscopy, 34 were positive
by MODS, 40 were positive by LJ culture, and 43 were positive by
histology; the sensitivities were 36.5, 65.4, 76.9, and 82.7%, and
the negative predictive values (NPVs) were 70.8, 81.6, 87.0, and
89.9%, respectively. HIV-positive patients were more likely than
HIV-negative patients to have positive auramine microscopy re-
FIG 1 Flow diagram indicating procedures following patient enrollment. For auramine microscopy, the visualization of one or more AFB per 100 fields was
considered positive (27). DST of all samples positive by LJ culture was performed. One strain per patient was tested. UPCH, Universidad Peruana Cayetano
Heredia; NALC, N-acetyl-L-cysteine; H&E, hematoxylin and eosin; PAS, periodic acid-Schiff.
TABLE 1 Demographic information and test results for all study participants
Parameter
TB positive
(n 52)
TB negative
(n 80) P value
Auramine
positive
(n 19)
MODS
positive
(n 34)
LJ positive
(n 40)
Histological
diagnosis of
TB (n 43)
Total
(n 132)
No. (%) of femalesa 23 (44.2) 34 (42.5) 0.86 3 (15.8) 13 (38.2) 16 (40.0) 22 (51.2) 57 (43.2)
Median age, yr (IQR)b 39 (26–46) 41 (27–55) 0.38 32 (29–40) 32 (25–48) 32.5 (25–46) 35 (24–47) 40 (25–52)
No. (%) HIV positivea 20 (38.5) 34 (42.5) 0.72 13 (68.4) 12 (35.3) 14 (35.0) 15 (34.9) 54 (40.9)
Median no. of CD4 cells/mm3 (IQR)b 75 (27–218) 163 (121–271) 0.18 87 (25–140) 75 (22–163) 87 (25–140) 63 (25–219) 156 (41–234)
No. (%) with positive sputum smeara 4 (7.7) 0 (0) 0.02 4 (2.1) 3 (8.8) 4 (10.0) 3 (7.0) 4 (3.0)
No. (%) on TB treatment for1 wka 5 (9.6) 7 (8.8) 1.00 5 (26.3) 4 (11.8) 4 (10.0) 3 (7.0) 12 (9.7)
No. (%) with previous TBa 10 (19.2) 13 (16.3) 0.65 3 (15.8) 2 (5.9) 4 (10.0) 7 (16.3) 23 (17.4)
No. (%) with normal CXRa 27 (51.9) 38 (47.5) 0.375 8 (42.1) 15 (48.4) 18 (45.0) 22 (51.2) 65 (49.2)
No. (%) with abnormalc CXRa 18 (34.6) 28 (35.0) 0.558 10 (52.6) 14 (44.1) 16 (40.0) 14 (32.6) 46 (34.8)
a Compared by Fisher’s exact test.
b Compared by Wilcoxon rank sum test.
c Where specified, abnormalities included pulmonary infiltrates and/or consolidation (n 14), pleural effusion(s) (n 14), hilar and/or paratracheal adenopathy (n 9),
cavitation (n 1), and miliary TB (n 1).
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sults (65 and 18.8%, respectively; P 0.001). TBwas detected in 5
of 12 patients already undergoing TB therapy (5 by microbiolog-
ical methods and 3 by histological analysis; all 5 were HIV positive
with CD4 counts of250/mm3). Physicians suspected TB in 48
TB-positive and 53 TB-negative patients; thus, the sensitivity,
specificity, positive predictive value (PPV), and NPV of the phy-
sician’s presumptive TB diagnosis were 92.3, 33.8, 47.5, and
87.1%, respectively.
Forty-two patients had one or more positive microbiological
test results (Fig. 2, bottom). MODS, TEMA, and the proportion
method detected multidrug-resistant TB (MDR-TB) in two pa-
tients and isoniazid monoresistance in one patient. MDR-TB was
identified by TEMA and the proportion method in one patient
whose isolate grew on LJ culture but not by MODS. The propor-
tion method reported low-level isoniazid resistance in five addi-
tional samples; all others were fully drug susceptible according to
all of the methods used.
Positive results were communicated after a median interval of
13 days (interquartile range [IQR], 11 to 18 days; n  57) for
MODSand 22days (IQR, 17 to 28 days;n 78) for LJ culture (P
0.001), and negative results were communicated after a median
interval of 41 days (IQR, 38 to 41 days; n 186) forMODS and 63
days (IQR, 59 to 64 days; n 163) for LJ culture (P 0.001). The
median time to positivity for patients undergoing TB treatment
was 9.5 days (IQR, 6.5 to 21 days; n 6) for MODS and 15 days
(IQR, 15 to 17 days; n 8) for LJ culture. Auramine microscopy
results were communicated after 1 day for both positive (IQR, 1 to
2 days; n 42) and negative (IQR, 1 to 3 days; n 145) samples.
As DST was performed in batches, the time to results is not avail-
able; however, laboratory data indicate assay times of 40 to 45 days
for the proportion method and 7 to 10 days for TEMA.
Contamination was reported for 38 (26.6%; n  143) direct
MODS assays and for none performed following sample decon-
tamination (n 144). For LJ culture, 42 (29.4%; n 143) direct
and 4 (2.8%; n 144) decontaminated cultures were reported as
contaminated. Sensitivity and NPV were higher following decon-
tamination than with direct processing by all of the microbiolog-
ical methods used (Table 2). This finding persisted when contam-
inated specimens were excluded from the analysis. There was no
difference in the time to positivity between predecontaminated
and directly processed specimens.
Paraffin blocks from 121 patients were obtained for full histo-
pathological assessment, and a consensus diagnosis was reached
for 117 patients (Table 3). The most frequent histological diagno-
sis was TB (34.2%). AFB were observed in eight specimens on ZN
staining; all were culture positive, and six were positive by aura-
mine microscopy. Interobserver agreement was high for the pres-
ence of granulomas (  0.83) and caseous necrosis (  0.90)
but not AFB (  0.18).
This study is the first prospective evaluation of MODS culture
for solid tissue specimens.MODSaccurately detectedTB in lymph
node tissue specimens. In contrast to data from respiratory spec-
imens (20),MODSwas less sensitive than LJ culture (65.4%versus
76.9%) but almost twice as sensitive as auramine microscopy
(36.5%). Comparable to other studies of TB lymphadenitis, the
sensitivities of all of the microbiological assays used were lower
than those reported for sputum specimens (3, 6, 21, 22), possibly
because of the light bacterial load in tissue and/or clumping of
pathogens (6). Accordingly, the time to results was longer than
that reported for sputum specimens (13 versus 7 days for MODS,
26 versus 22 days for LJ culture) (7). With both culture methods,
contamination rates on direct testing were high. Specimen prede-
contamination increased the sensitivity of all diagnostic tests.
MODS provided accurate data on isoniazid and rifampin re-
sistance simultaneously with diagnosis, which facilitates the
timely initiation of appropriate regimens andmay prevent further
development of resistance. The MDR-TB rate was similar to rates
previously documented in Lima (7.7% versus 8.6%) (23), al-
though the sample numbers in this study were small; further pro-
spective testing of greater sample numbers is needed to confirm
the accuracy of resistance testing. Universal DST is recommended
in regions where the primary MDR-TB rates exceed 3% (24), and
MODS may be particularly valuable in such settings.
Physicians have overestimated rates of TB, which can lead to
overtreatment and delays in obtaining correct diagnoses. Uni-
versal access to MODS has the potential to improve the out-
comes of extrapulmonary TB similar to those of respiratory
disease (25). Performance of MODS and LJ culture in parallel
would combine the benefits of rapidity and simultaneous drug
FIG 2 Venn diagrams showing numbers of patients positive by different test
modalities. (Top) Positivity for TB by auramine microscopy, TB culture, and
histological evaluation (n  132). Twelve patients were positive by all three
methods, 26 were positive by two methods, and 14 were positive by only one
method. Two patients were positive only by auramine microscopy. (Bottom)
Positivity by microbiological methods of TB detection (n 132). All patients
positive byMODSwere also positive by LJ culture. Eight patients were positive
by auramine microscopy (n 3) and/or LJ culture (n 6) but not byMODS.
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resistance data afforded by MODS and the higher sensitivity of
LJ culture.
Nineteen patients had discrepant microbiological and his-
tological results. Similar findings have been reported elsewhere
(6). Possible explanations include failure of the host to gener-
ate a typical histopathological response, visualization of killed
bacilli in patients undergoing TB treatment, and recent use of
antibiotics with some antimycobacterial effect (26). Different
test modalities may be beneficial for these different patient
groups. The concordance between the pathologists’ findings
and diagnoses was high, although agreement with respect to
AFB visualization was poor. The pathologists were blind to
clinical information, whereas in practice, findings are inter-
preted within a clinical context and accuracy may be greater
than that observed in this study.
In conclusion, although MODS is less sensitive than LJ cul-
ture, it is able to accurately diagnose TB from lymph node
tissue significantly faster. It can also correctly detect resistance
to rifampin and isoniazid simultaneously with diagnosis, en-
abling prompt initiation of targeted treatment. No single diag-
nostic test for TB has all of the properties of an ideal test, and
multiple methods should be used in the diagnostic workup of
patients with lymphadenopathy. MODS may have an impor-
tant role to play in the diagnosis of TB in resource-limited
settings. These data support the expansion of MODS to solid
tissue specimens within programmatic guidelines.
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TABLE 2 Comparison of results and test characteristics for specimen processing following decontamination and direct inoculation of specimens
without prior decontamination
Parameter
Auramine microscopy MODS LJ culture
Decontaminated
(n 144)
Direct
(n 143)
Decontaminated
(n 144)
Direct
(n 143)
Decontaminated
(n 144)
Direct
(n 143)
No. (%) positive 22 (15.3) 20 (14.0) 39 (27.1) 18 (12.6) 46 (31.9) 32 (22.4)
No. (%) negative 122 (84.7) 123 (86.0) 101 (70.1) 85 (59.4) 94 (65.3) 69 (48.3)
No. (%) indeterminate 0 0 4 (2.8) 2 (1.4) 0 0
No. (%) contaminated 0 0 0 38 (26.6) 4 (2.8) 42 (29.4)
All specimens
% Sensitivity 44.9 40.8 79.6 37.5 93.9 66.7
% NPV 77.9 77.2 90.5 76.0 97.0 88.6
Contaminated specimens excluded
% Sensitivity 44.9 40.8 79.6 54.5 93.9 91.4
% NPV 77.9 77.2 90.5 82.8 96.8 95.7
Overall
% Sensitivity 44.9 81.6 93.9
% NPV 77.9 91.3 96.9
TABLE 3 Histopathological findings and histological diagnoses of
patients for whom a consensus diagnosis was reached by two or more
pathologists
Result
No. (%) of samples with
agreement between2
pathologists (n 117)
Kappa
value
Histopathological findings
AFB on ZN staining 2 (1.7) 0.18
Granuloma 42 (35.9) 0.83
Caseous material 34 (29.1) 0.90
Histological diagnoses
TBa 40 (34.2) 0.85
Lymphoma 15 (12.8) 0.66
KSb 3 (2.6) 0.87
Other malignancy 16 (13.7) 0.88
Hyperplasia 31 (26.5) 0.64
Histoplasmosis 1 (0.85) 0.24
Other 11 (9.4) 0.33
a Where the agreement was between only two pathologists, the diagnosis of a third
pathologist was reactive changes (n 3), lymphoma (n 1), non-lymph-node tissue
(n 2), or other/unspecified (n 2). Both patients with a non-lymph-node tissue
diagnosis were culture positive for TB.
b KS, Kaposi’s sarcoma.
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